Please assess the completion status of the following clinical trial:

Trial Title: TMC125-C223: TMC125 in HIV-1 Infected Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 plasma viral load at screening \>1000 copies/ml~* Documented genotypic evidence of resistance to currently available NNRTIs~* Previous NRTI experience for at least 3 months~* 3 primary PI mutations at screening~Exclusion Criteria:~* Chronic HBV and/or HCV with elevated liver function tests \> 3x upper normal limits~* Any grade 3 or 4 toxicity according to the ACTG grading severity list (except for grade 3 glucose and asymptomatic triglyceride/cholesterol grade 3 or 4 elevation)~* Previous permanent discontinuation of any NNRTI due to cutaneous events.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).